- Home
- NRXS vs RLYB Comparison
NRXS vs RLYB Comparison
Compare NRXS & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXS | RLYB |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 24.1M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NRXS | RLYB |
|---|---|---|
| Price | $2.75 | $0.74 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 49.4K | ★ 176.7K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,362,320.00 | $674,000.00 |
| Revenue This Year | $31.05 | $17.61 |
| Revenue Next Year | $137.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.89 | 12.71 |
| 52 Week Low | $1.33 | $0.22 |
| 52 Week High | $6.20 | $1.20 |
Technical Indicators
Market Signals| Indicator | NRXS | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 47.93 | 62.81 |
| Support Level | $2.50 | $0.63 |
| Resistance Level | $2.76 | $0.80 |
| Average True Range (ATR) | 0.15 | 0.04 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 45.47 | 63.62 |
Price Performance
Historical ComparisonAbout NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.